News J&J to work with Orthocell on new regenerative stem cell the... Multi-centre trial of Ortho-ATI technology planned for early 2017.
News Novartis, BMS, Janssen unveil R&D deals Companies announce eye-catching R&D plans ahead of conference.
News Johnson & Johnson back in 'exclusive' talks to buy Actelion Deal expected to be worth around $30 billion.
News Sanofi outbids J&J for Actelion merger - reports Reports suggest Sanofi could pay $30 billion for Swiss biotech.
News ADARx, Trex, and Retension take aim at IPOs The appetite among biotechs for IPOs shows no signs of being satisfied, with three more – ADARx, TRex, and Retension – making their intentions known.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
